Nestlé Introduces Food Line Geared Towards Consumers of Ozempic and Similar Weight-Loss Medications
Nestlé Unveils New Food Line for Users of Weight-Loss Medications, Anticipating a $30 Billion Market Surge
Launching under the banner of Vital Pursuit, Nestlé’s latest venture introduces 12 tailored products, including frozen protein pasta, sandwich melts, and pizzas. Each item boasts elevated protein content and vital nutrients like iron, vitamin A, and potassium, meticulously portioned to align with the appetite of weight-loss medication users.
This marks Nestlé’s debut in crafting a food brand expressly for consumers of glucagon-like peptide 1 (GLP-1) agonists. These drugs, such as semaglutide in Novo Nordisk’s Wegovy and Ozempic, and tirzepatide in Eli Lilly’s Mounjaro and Zepbound, are renowned for their efficacy in managing Type 2 diabetes and facilitating weight loss.
As GLP-1 medications gain prominence for their weight-reduction benefits, Nestlé aims to cater to evolving consumer preferences. Walmart U.S. CEO John Furner noted a discernible shift in shopper behavior during a November earnings call, signaling a potential transformation in market dynamics.
Earlier this month, Novo Nordisk informed FOX Business that a minimum of 25,000 Americans are initiating Wegovy treatment weekly, with this number steadily increasing.
The Danish pharmaceutical leader, in response to escalating demand, has been expanding its production capabilities. Presently, there’s a notable surge in U.S. patients starting the medication, quadrupling the figures recorded in December 2023.
In 2023, the American Pharmacists Association reported that one out of every 60 adults received prescriptions for GLP-1 medications.
Projections from JPMorgan indicate that by 2030, the U.S. could see approximately 30 million GLP-1 users, constituting roughly 9% of the total population. The market’s value is anticipated to surpass $100 billion by the same year, with demand being fueled by both diabetes and obesity treatments.
